Document Detail

Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies.
MedLine Citation:
PMID:  19620851     Owner:  NLM     Status:  MEDLINE    
Although the benefits of clozapine have been well demonstrated in resistant schizophrenia, the frequency of adverse events is of particular concern: up to 76% of patients to whom clozapine was prescribed experienced an adverse event, with a discontinuation rate of 17%. In addition to its major clinical side effect, agranulocytosis, clozapine is reported to induce inflammatory syndromes with polyserositis. Apart from sparse case reports, no study has yet addressed this particularly interesting issue. With the aim of improving the outcome of clozapine-treated patients, we undertook a review of the literature to characterize the clinical features of clozapine-induced serositis, its pathophysiology, and to propose strategies of clinical management.
Fayçal Mouaffak; Raphael Gaillard; Elizabeth Burgess; Hanane Zaki; Jean Pierre Olié; Marie-Odile Krebs
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  32     ISSN:  1537-162X     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:    2009 Jul-Aug
Date Detail:
Created Date:  2009-07-31     Completed Date:  2009-10-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  219-23     Citation Subset:  IM    
Center of Psychiatry and Neurosciences, INSERM U894.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / adverse effects*
Clozapine / adverse effects*
Schizophrenia / drug therapy*,  physiopathology
Serositis / chemically induced*,  physiopathology,  therapy
Withholding Treatment
Reg. No./Substance:
0/Antipsychotic Agents; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Investigating the efficacy of paroxetine in developmental stuttering.
Next Document:  Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: m...